XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Core Viewpoint - XTL Biopharmaceuticals Ltd. has received a notification from Nasdaq indicating that it does not meet the continued listing requirement of maintaining a minimum of $2,500,000 in stockholders' equity, reporting a deficit of $47,000 as of June 30, 2025 [1][2]. Group 1: Nasdaq Notification - The notification does not lead to immediate delisting of the Company's American Depositary Shares (ADSs), which will continue to trade under the symbol "XTLB" [2]. - The Company has 45 calendar days, until March 6, 2026, to submit a plan to regain compliance, with the possibility of an extension of up to 180 days if the plan is accepted [2]. Group 2: Compliance Efforts - XTL is currently evaluating options to regain compliance with Nasdaq's continued listing requirements and intends to make reasonable efforts to achieve this [3]. - There is no assurance that the Company will successfully regain compliance with the listing requirements [3]. Group 3: Company Overview - XTL Biopharmaceuticals Ltd. is an IP Portfolio company that holds 100% of The Social Proxy Ltd. and has an IP portfolio including hCDR1 for Lupus (SLE) and Sjögren's Syndrome (SS) [4]. - The Company actively seeks strategic collaborations and acquisitions to expand its therapeutic portfolio into high-value disease areas [4].